- Home
- SLRX vs WINT Comparison
SLRX vs WINT Comparison
Compare SLRX & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- WINT
- Stock Information
- Founded
- SLRX N/A
- WINT 1992
- Country
- SLRX United States
- WINT United States
- Employees
- SLRX N/A
- WINT N/A
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLRX Health Care
- WINT Health Care
- Exchange
- SLRX Nasdaq
- WINT Nasdaq
- Market Cap
- SLRX 2.1M
- WINT 2.2M
- IPO Year
- SLRX N/A
- WINT 1995
- Fundamental
- Price
- SLRX $0.50
- WINT $0.55
- Analyst Decision
- SLRX
- WINT Hold
- Analyst Count
- SLRX 0
- WINT 1
- Target Price
- SLRX N/A
- WINT $350.00
- AVG Volume (30 Days)
- SLRX 6.2M
- WINT 18.3M
- Earning Date
- SLRX 08-19-2025
- WINT 08-18-2025
- Dividend Yield
- SLRX N/A
- WINT N/A
- EPS Growth
- SLRX N/A
- WINT N/A
- EPS
- SLRX N/A
- WINT N/A
- Revenue
- SLRX N/A
- WINT N/A
- Revenue This Year
- SLRX N/A
- WINT N/A
- Revenue Next Year
- SLRX N/A
- WINT N/A
- P/E Ratio
- SLRX N/A
- WINT N/A
- Revenue Growth
- SLRX N/A
- WINT N/A
- 52 Week Low
- SLRX $0.45
- WINT $0.36
- 52 Week High
- SLRX $7.20
- WINT $663.44
- Technical
- Relative Strength Index (RSI)
- SLRX 37.62
- WINT 38.51
- Support Level
- SLRX $0.59
- WINT $0.50
- Resistance Level
- SLRX $2.31
- WINT $1.02
- Average True Range (ATR)
- SLRX 0.18
- WINT 0.10
- MACD
- SLRX -0.02
- WINT -0.04
- Stochastic Oscillator
- SLRX 2.27
- WINT 6.74
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.